Quantcast
Last updated on April 17, 2014 at 1:21 EDT

DNA2.0 Opens Gene Marketplace

May 12, 2011

Xbrane Bioscience’s Rhamexâ“¢ Protein Expression System Becomes First Set of Vector Constructs Available Through Gene Designer””DNA2.0′s Groundbreaking Gene Assembly and Design Application

Boston, MA (PRWEB) May 11, 2011

PEGS Summit: DNA2.0 today announced that it will offer third-party genetic constructs through the company’s groundbreaking gene assembly and design application, Gene Designer. The Rhamexâ“¢ protein expression systems from Xbrane Bioscience will be the first commercial constructs that users will be able to access and order directly through Gene Designer. In addition to Xbrane’s Rhamex expression system, DNA2.0 will begin to offer a wide range of standard biological parts so that users may easily create genetic constructs from standard building blocks with Gene Designer.

“We’re creating a marketplace for synthetic biology, with Gene Designer serving as the “app store” for molecular biologists,” said Dr. Claes Gustafsson, Chief Operating Officer at DNA2.0. “Not only does Gene Designer offer a powerful design application with rich graphics and a patented drag-and-drop functionality, but now users will have access to license powerful preassembled and validated constructs such as Xbrane’s expression system, fundamentally streamlining the process of creating and purchasing genes.”

Xbrane’s bacterial protein expression system is tightly controlled by rhamnose and enables high expression yields, even for toxic and otherwise challenging proteins. Xbrane’s Rhamex system is tightly regulated at the individual cell level and at the same time capable of producing high protein yields of bioactive and correctly folded proteins. The Rhamex system is E. coli strain independent and can also be used in other Gram-negative bacteria.

“While research scientists and production technologists are often limited in their choice of bacterial expression systems for the production of toxic proteins, we are excited to partner with DNA2.0 to offer our affordable, user-friendly Rhamex expression systems through Gene Designer,” said Lykke Abdon, Director of Marketing of Xbrane Bioscience. “We are entering a new age of bioengineering that relies on the availability of the kind of preassembled, specialized DNA building blocks that Xbrane makes, and DNA2.0′s Gene Designer offers an exceptional marketplace for sharing, designing and constructing novel genetic constructs.”

DNA2.0 intends to expand the catalogue of DNA components available within Gene Designer and looks forward to partnering with a wide range of developers to offer users a rich marketplace of preassembled constructs””making the design and assembly of genes faster and easier than ever before.

About DNA2.0

Founded in 2003, DNA2.0 is the leading gene synthesis and protein engineering company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif.

About Xbrane Bioscience

Xbrane Bioscience develops and commercializes platforms for the efficient and cost-effective production of proteins and vaccines. The company was founded early 2008, as a spin-off company from the world-leading Center for Biomembrane Research at the Department of Biochemistry & Biophysics of Stockholm University, Sweden. The company has developed and sells two bacterial based protein expression systems providing unprecedented versatility, Xbrane Lemo System̢Ң and Xbrane Rhamex System̢Ң. Xbrane Bioscience is currently further expanding its portfolio of innovative technologies, including platforms for the development of multivalent vaccines and the efficient production of toxic and unstable proteins. For more information about Xbrane Bioscience visit http://www.xbrane.com.

For more information, please visit http://www.dna20.com or email Claes Gustafsson, COO: cgustafsson(at)DNA20(dot)com.

For more information about Xbrane visit http://www.xbrane.com or email Lykke Abdon: lykke(at)xbrane(dot)com

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/5/prweb8408724.htm


Source: prweb